South Korean AI company Neurophet has entered a memorandum of understanding (MoU) with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) to facilitate imaging monitoring infrastructure for therapies related to the disease.
The agreement is aimed at providing support to healthcare professionals taking part in ALZ-NET while improving the quality of care for Alzheimer’s patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The collaboration targets increased awareness of amyloid-related imaging abnormalities (ARIA) monitoring.
Key products in this partnership include Neurophet Aqua, a brain neurodegeneration imaging analysis tool; Neurophet Scale PET, a quantitative positron emission tomography (PET) imaging analysis solution; and the Neurophet Aqua AD Plus integrated brain imaging product.
All three solutions hold 510(k) clearance from the US Food and Drug Administration (FDA). Various participating medical centres and neuroimaging facilities are anticipated to adopt these tools for ongoing clinical care.
ALZ-NET is sponsored by the Alzheimer’s Association and managed by the American College of Radiology (ACR).
American College of Radiology neuroradiology research committee chair and ALZ-NET imaging workgroup member Ana Franceschi said: “We are pleased to collaborate with Neurophet to bring their innovative imaging solution to ALZ-NET sites. Strengthening imaging infrastructure across the network is essential to providing high-quality care as Alzheimer’s treatment continues to advance.”
Neurophet co-CEO Jake Junkil Been said: “With ALZ-NET, Neurophet aims to contribute to the establishment of an imaging-based monitoring infrastructure that is essential in the era of Alzheimer’s therapies. We will contribute to enhancing the overall quality of the Alzheimer’s treatment ecosystem in the US.”
In October 2024, Neurophet partnered with biopharma AriBio to develop a platform aimed at accelerating Alzheimer’s diagnoses.
